ARCHIVES

Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

January 25, 2002

Cancer researchers support “responsible” human stem cell research.

July 22, 2005

Coalition Demands Role In Deciding spending will Target Healy, Broder, Chabner

October 16, 1992

NIH Solicits Grant applications For New Type Of Small Business Award; 40 To Be Funded

September 10, 1993

GAO Offers Two Suggestions For Plant Screening

April 4, 1980

CPRU Program Gets Basic Concept Approval

October 2, 1987